ADALIMUMAB

adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices

ADALIMUMAB (12381P)

adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices
12381P
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Complex refractory Fistulising Crohn disease
Treatment phase: Initial treatment - Initial 1 (new patient or recommencement of treatment after a break in biological medicine of more than 5 years)

Restriction

Indication: Complex refractory Fistulising Crohn disease
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

Restriction

Indication: Complex refractory Fistulising Crohn disease
Treatment phase: Initial 1 (new patient or recommencement of treatment after a break in biological medicine of more than 5 years), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 3 Max qty units: 6 # of repeats: 0 DPMQ: $1,464.78 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Hadlima
Humira
Hyrimoz
Yuflyma